Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model

Authors

  • Xin Yang,

    1. Laboratory of Experimental Neurosurgery, Université Libre de Bruxelles, Brussels, Belgium
    2. Multidisciplinary Research Institute (IRIBHM), Université Libre de Bruxelles, Brussels, Belgium
    Search for more papers by this author
  • Birgit Mertens,

    1. Department of Pharmaceutical Chemistry, Drug Analysis and Drug Information (Research Group Experimental Neuropharmacology), Vrije Universiteit Brussel, Brussels, Belgium
    Search for more papers by this author
  • Enni Lehtonen,

    1. Laboratory of Experimental Neurosurgery, Université Libre de Bruxelles, Brussels, Belgium
    2. Multidisciplinary Research Institute (IRIBHM), Université Libre de Bruxelles, Brussels, Belgium
    Search for more papers by this author
  • Linda Vercammen,

    1. Laboratory for Neurobiology and Gene Therapy, Katholieke Universiteit Leuven, Leuven, Belgium
    Search for more papers by this author
  • Olivier Bockstael,

    1. Laboratory of Experimental Neurosurgery, Université Libre de Bruxelles, Brussels, Belgium
    2. Multidisciplinary Research Institute (IRIBHM), Université Libre de Bruxelles, Brussels, Belgium
    Search for more papers by this author
  • Abdelwahed Chtarto,

    1. Laboratory of Experimental Neurosurgery, Université Libre de Bruxelles, Brussels, Belgium
    2. Multidisciplinary Research Institute (IRIBHM), Université Libre de Bruxelles, Brussels, Belgium
    Search for more papers by this author
  • Marc Levivier,

    1. Laboratory of Experimental Neurosurgery, Université Libre de Bruxelles, Brussels, Belgium
    2. Present address: Department of Neurosurgery, CHUV, Lausanne, Switzerland
    Search for more papers by this author
  • Jacques Brotchi,

    1. Laboratory of Experimental Neurosurgery, Université Libre de Bruxelles, Brussels, Belgium
    Search for more papers by this author
  • Yvette Michotte,

    1. Department of Pharmaceutical Chemistry, Drug Analysis and Drug Information (Research Group Experimental Neuropharmacology), Vrije Universiteit Brussel, Brussels, Belgium
    Search for more papers by this author
  • Veerle Baekelandt,

    1. Laboratory for Neurobiology and Gene Therapy, Katholieke Universiteit Leuven, Leuven, Belgium
    Search for more papers by this author
  • Sophie Sarre,

    1. Department of Pharmaceutical Chemistry, Drug Analysis and Drug Information (Research Group Experimental Neuropharmacology), Vrije Universiteit Brussel, Brussels, Belgium
    Search for more papers by this author
  • Liliane Tenenbaum

    Corresponding author
    1. Laboratory of Experimental Neurosurgery, Université Libre de Bruxelles, Brussels, Belgium
    2. Multidisciplinary Research Institute (IRIBHM), Université Libre de Bruxelles, Brussels, Belgium
    • Laboratory of Experimental Neurosurgery/IRIBHM, CP602, ULB-Hôpital Erasme, Brussels, Belgium.
    Search for more papers by this author

Abstract

Background

Efficient protection of dopaminergic neurons against a subsequent 6-hydroxydopamine lesion by glial cell line-derived neurotrophic factor (GDNF) gene delivery has been demonstrated. By contrast, the neurorestorative effects of GDNF administered several weeks after the toxin have been less characterized. In particular, whether these were permanent or dependent on the continuous presence of GDNF remains elusive.

Methods

A tetracycline-inducible adeno-associated virus (AAV)-1 vector expressing human GDNF cDNA was administered unilaterally in the rat striatum 5 weeks after 6-hydroxydopamine. Rats were treated with doxycycline (dox) or untreated from the day of vector injection until sacrifice (4 or 14 weeks). A sub-group was dox-treated for 7 weeks then untreated until 14 weeks. The motor behavior was assessed by amphetamine-induced rotations and spontaneous forelimb asymmetry. The amounts of tyrosine hydroxylase (TH), serine-40-phosphorylated TH (S40-TH) and aromatic amino acid decarboxylase (AADC) proteins were compared by western blotting and the dopamine levels quantified by high-performance liquid chromatography.

Results

Dox-dependent behavioral improvements were demonstrated 4 weeks post-vector injection. At later time points, spontaneous partial recovery was observed in all rats, but no further improvement was found in dox-treated animals. TH levels were significantly increased in dox-treated rats at all time points. By contrast, striatal dopamine and S40-TH were increased at 4 weeks, but not 14 weeks, and AADC remained unchanged. Dox withdrawal after 7 weeks, resulted in TH levels comparable to the controls at 14 weeks.

Conclusions

Delayed GDNF gene delivery only transiently improved dopaminergic function. Over the long term, TH was more abundant, but not functional, and the increase was lost when GDNF gene expression was switched off. Copyright © 2009 John Wiley & Sons, Ltd.

Ancillary